BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30617223)

  • 1. IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.
    Eriksson E; Milenova I; Wenthe J; Moreno R; Alemany R; Loskog A
    J Immunol; 2019 Feb; 202(3):787-798. PubMed ID: 30617223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment.
    Eriksson E; Moreno R; Milenova I; Liljenfeldt L; Dieterich LC; Christiansson L; Karlsson H; Ullenhag G; Mangsbo SM; Dimberg A; Alemany R; Loskog A
    Gene Ther; 2017 Feb; 24(2):92-103. PubMed ID: 27906162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.
    Eriksson E; Milenova I; Wenthe J; Ståhle M; Leja-Jarblad J; Ullenhag G; Dimberg A; Moreno R; Alemany R; Loskog A
    Clin Cancer Res; 2017 Oct; 23(19):5846-5857. PubMed ID: 28536305
    [No Abstract]   [Full Text] [Related]  

  • 4. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions.
    Garcia-Bates TM; Palma ML; Shen C; Gambotto A; Macatangay BJC; Ferris RL; Rinaldo CR; Mailliard RB
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling.
    Naseri S; Cordova MM; Wenthe J; Lövgren T; Eriksson E; Loskog A; Ullenhag GJ
    J Cell Mol Med; 2024 Apr; 28(7):e18162. PubMed ID: 38494863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
    Zhang Y; Velez-Delgado A; Mathew E; Li D; Mendez FM; Flannagan K; Rhim AD; Simeone DM; Beatty GL; Pasca di Magliano M
    Gut; 2017 Jan; 66(1):124-136. PubMed ID: 27402485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
    Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
    Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD40 signalling induces IL-10-producing, tolerogenic dendritic cells.
    Tuettenberg A; Fondel S; Steinbrink K; Enk AH; Jonuleit H
    Exp Dermatol; 2010 Jan; 19(1):44-53. PubMed ID: 19889024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
    Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
    J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
    Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
    Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
    Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
    Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells.
    Luft T; Luetjens P; Hochrein H; Toy T; Masterman KA; Rizkalla M; Maliszewski C; Shortman K; Cebon J; Maraskovsky E
    Int Immunol; 2002 Apr; 14(4):367-80. PubMed ID: 11934873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment.
    Loskog A; Dzojic H; Vikman S; Ninalga C; Essand M; Korsgren O; Totterman TH
    J Immunol; 2004 Jun; 172(11):7200-5. PubMed ID: 15153545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.
    Horn LA; Riskin J; Hempel HA; Fousek K; Lind H; Hamilton DH; McCampbell KK; Maeda DY; Zebala JA; Su Z; Schlom J; Palena C
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
    Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
    J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.